Vertex Pharmaceuticals announced that Senior Vice President Paul Negulescu has been named a winner of the 2025 Lasker~DeBakey Clinical Medical Research Award. The award recognizes his pivotal role in the development of TRIKAFTA, a life-saving triple-drug combination therapy for cystic fibrosis (CF).
Dr. Negulescu, along with former Vertex scientist Jesús González and Professor Michael Welsh, is honored for groundbreaking work in discovering and developing the first approved medicines that address the underlying cause of CF. Vertex has brought five transformative medicines to CF patients, fundamentally changing disease treatment.
The Lasker Awards are widely regarded as America’s preeminent biomedical research prize, with 101 Laureates also receiving the Nobel Prize. This recognition underscores Vertex's scientific leadership and the profound impact of its research on global health.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.